Thanks for finding us at WCLC

Who We Are and What We Do

​​​​​​​One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases

Thanks for finding us at WCLC

Who We Are and What We Do

​​​​​​​One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find new treatments for these deadly diseases

Highlights From Your Congress


What’s Of Interest


Pfizer Oncology Collaborating to Improve Patient Centricity

Investigator Resources

Focus on Health Equity

Commitment To Oncology


Supporting Our Patients

Category list

Scheduled Events

Product Theaters


Product Theater:

An Overview of Efficacy and Safety Data for a First-Line Treatment Option for ALK+ Metastatic NSCLC Product Theater
Date and Time: Available on-demand on the WCLC virtual platform September 1 - September 30


Abstracts
​​​​​​​

Abstract title:

Lorlatinib for previously-treated ALK-positive advanced NSCLC: primary efficacy and safety data from a Phase 2 study in China
Study: B7461024


Abstract title:

Lorlatinib in First Line Treatment of Patients with ALK-Positive NSCLC: a Network Meta-analysis
Study: Network meta-analysis


Abstract title:

Therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive NSCLC in real-world
Study: RWD


Abstract title:

Overall Survival from a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer
Study: A8081063


Abstract title:

Real-world data of NGS diagnostic biomarker testing for lung cancer patients in Japan
Study: RWD

Opportunities To Connect


Connect with Pfizer
through our Contact Form

Connect with Pfizer

Please fill out the form below. A member from the team will respond accordingly.

By providing your email address, you agree to receive an email response from Pfizer to your inquiry. Your email address will only be used to respond to your inquiry. The information you submit will be governed by our Privacy Policy.

All fields marked with an asterisk ( *) are required.

Thank you for
contacting Pfizer.

A team member will respond to your inquiry.

X

PF-06863135 is an investigational compound and has not been approved by any Regulatory Authority as safe or effective for any use. The preclinical and in vitro evidence presented here may not necessarily correlate with clinical outcomes.